Top Markets
#1 Islamic Coin Islamic Coin +154.32%
#2 PulseChain PulseChain +49.10%
#3 DogBull DogBull +34.96%
#4 BOOK OF MEME BOOK OF MEME +33.86%
#5 Ergo Ergo +24.35%
#6 rsERG rsERG +20.19%
#7 Janction Janction +18.21%
#8 Bio Protocol Bio Protocol +17.85%
#9 RedStone RedStone +14.71%
#10 edgeX edgeX +14.62%
Coin of the day
Islamic Coin Islamic Coin
Settings
Language
ENGLISH
Currency
USD
Theme
NurExone Biologic Inc. NurExone Biologic Inc.

NurExone Biologic Inc.

NRX
Rank in Stocks #27133
NurExone Biologic Inc., a pharmaceutical technology company, develops a... NurExone Biologic Inc., a pharmaceutical technology company, develops a platform for biologically guided exosome-based therapies for the treatment of central nervous system injuries. Its lead product, ExoPTEN, has demonstrated strong preclinical data supporting clinical potential in treating acute spinal cord and optic nerve injury. The company was founded on June 27, 2011 and is headquartered in Toronto, Canada.
Share Price
$0.47705898
Last synced: 2026-08-19
Market Cap
$35.01M
Change (1 day)
8.33%
Change (1 year)
-16.23%
Country
CA
Trade NurExone Biologic Inc. (NRX)

Category

Healthcare
P/E ratio for NurExone Biologic Inc. (NRX)
P/E ratio as of 2026 TTM: 0
According to NurExone Biologic Inc. latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 0. At the end of 2026 the company had a P/E ratio of 0.
P/E ratio history for NurExone Biologic Inc. from 2026 to 2026
P/E ratio at the end of each year
Year P/E Ratio Change
Not enough data for the provided dates.
P/E ratio for similar companies or competitors
Company P/E Ratio P/E Ratio Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 29.20 -
US
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 -7.93 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 30.62 -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 32.46 -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.

Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.